Savara, Inc. (SVRA): Price and Financial Metrics


Savara, Inc. (SVRA): $2.39

-0.13 (-5.16%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

SVRA Stock Price Chart Interactive Chart >

Price chart for SVRA

SVRA Price/Volume Stats

Current price $2.39 52-week high $2.82
Prev. close $2.52 52-week low $1.02
Day low $2.39 Volume 117,500
Day high $2.54 Avg. volume 334,112
50-day MA $1.86 Dividend yield N/A
200-day MA $1.54 Market Cap 272.57M

Savara, Inc. (SVRA) Company Bio


Savara Inc., a clinical-stage specialty pharmaceutical company, focuses on the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. The company is based in Austin, Texas.


SVRA Latest News Stream


Event/Time News Detail
Loading, please wait...

SVRA Latest Social Stream


Loading social stream, please wait...

View Full SVRA Social Stream

Latest SVRA News From Around the Web

Below are the latest news stories about SAVARA INC that investors may wish to consider to help them evaluate SVRA as an investment opportunity.

Why Shares of Savara Soared This Week

The clinical-stage biopharmaceutical company focuses on therapies to treat rare respiratory diseases.

Yahoo | January 27, 2023

Savara Announces New Employment Inducement Grant

AUSTIN, Texas, January 20, 2023--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to two new employees.

Yahoo | January 20, 2023

Private equity firms are Savara Inc.'s (NASDAQ:SVRA) biggest owners and were rewarded after market cap rose by US$25m last week

If you want to know who really controls Savara Inc. ( NASDAQ:SVRA ), then you'll have to look at the makeup of its...

Yahoo | January 5, 2023

H.C. Wainwright Reaffirms Their Buy Rating on Savara (SVRA)

In a report released today, Andrew Fein from H.C. Wainwright reiterated a Buy rating on Savara (SVRA - Research Report), with a price target of $3.00. The company's shares closed last Friday at $1.17.Fein covers the Healthcare sector, focusing on stocks such as Unity Biotechnology, Wave Life Sciences, and ACADIA Pharmaceuticals. According to TipRanks, Fein has an average return of -10.6% and a 35.48% success rate on recommended stocks. Currently, the analyst consensus on Savara is a Moderate Buy with an average price target of $3.00.

Christine Brown on TipRanks | November 14, 2022

Savara Reports Third Quarter 2022 Financial Results and Provides Business Update

AUSTIN, Texas, November 10, 2022--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the third quarter ending September 30, 2022 and provided a business update.

Yahoo | November 10, 2022

Read More 'SVRA' Stories Here

SVRA Price Returns

1-mo 37.36%
3-mo 104.27%
6-mo 39.77%
1-year 89.68%
3-year 9.63%
5-year -79.57%
YTD 54.19%
2022 25.00%
2021 7.83%
2020 -74.33%
2019 -40.82%
2018 -48.99%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7418 seconds.